(via NewsDirect)
Discussing the company's first-quarter milestones, Mazzo said the results are anticipated to be foundational for the company's future, potentially leading to provisional approval applications in
Mazzo highlighted Lisata's effective cash management, with over
Additionally, Mazzo discussed the rapid progress of the BOLSTER trial in cholangiocarcinoma, expected to provide early data points in 2025. The company plans to expand its trials and anticipates potential partnership announcements by year-end, driven by these developments.
Contact Details
+1 604-688-8158
NA-editorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source